ERAS - Erasca, Inc.
About Erasca, Inc. (https://www.erasca.com)
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Jonathan E. Lim | Co-Founder, Chairman & Chief Executive Officer | 1972 | $1,163,588 USD |
| David Chacko | Chief Financial Officer & Chief Business Officer | 1984 | $775,216 USD |
| Shannon Morris | Chief Medical Officer | 1970 | $772,700 USD |
| Ebun S. Garner | Chief Legal Officer & Corporate Secretary | 1972 | $607,440 USD |
| Michael D. Varney | Chairman of Research & Development, Scientific Advisory Board Member and Director | 1958 | $93,181 USD |
| Alison Tjosvold Milhous | Senior Vice President of Accounting | 1979 | – |
| Brian L. Baker | Senior Vice President of Finance | 1967 | – |
| Chandra D. Lovejoy | Chief Regulatory Affairs Officer | 1971 | – |
| Lisa Tesvich-Bonora | Chief People Officer | – | – |
| Nik Chetwyn | Chief Operating Officer | – | – |
| Robert Shoemaker | Chief Scientific Officer | 1981 | – |